NASDAQ · CRSP

CRISPR Therapeutics AG

$46.73 +$0.19 (+0.41%) 1D After hours
Session Pulse Overnight session 1 mentions on Wed · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$4.58B
Market cap
—
P/E · TTM
$4.10M
Revenue · TTM
−$568.53M
Net income
EPS · TTM $-6.62
Dividend yield —
Free cash flow −$401.18M
Beta · 1Y 1.81
EBITDA · TTM −$546.11M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 24
    The stock moved -11.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 24
  • Mar 30
    From its Feb 26 high, the share price fell 28%.

    Peak close $61.74 on Feb 26; trough close $44.34 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • Feb 26
    The stock moved +11.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.58B
Enterprise value$2.73B
Shares outstanding98.5M
52-wk range$44.12 – $78.48
Avg volume · 20D1.7M
Net cash $1.86B
Book value / share$21.11
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About CRISPR Therapeutics AG
IPO dateOct 19, 2016
Employees393

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S1,117.10
P/FCF—
EV/EBITDA—
EV/Sales664.67
Graham №—

Profitability

Gross —
Operating -13,774.6%
Net -13,856.5%
FCF -9,777.6%
ROE / ROIC -30.3% · 1,361.5%

Financial Health

Current ratio17.96
Quick ratio—
Debt / equity0.32
Debt / EBITDA -1.07
Net cash $1.86B
Working capital$2.31B

Cash Flow · TTM

Operating CF −$399.96M
Capex −$1.21M
Free cash flow −$401.18M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

2.3
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings